Skip to main content

Table 2 Base-case analysis expected costs and test performance

From: A PCR-based diagnostic testing strategy to identify carbapenemase-producing Enterobacteriaceae carriers upon admission to UK hospitals: early economic modelling to assess costs and consequences

Strategy

Expected cost per patient (£)

True positives (%)

False positives (%)

True negatives (%)

False negatives (%)

Culture testing

2166.37

0.6

18.7

80.7

0.0027

PCR testing

1704.24

0.6

3.4

96

0.024

Cost difference with PCR testing (£)

−462.13

   Â